Systemic Inflammation Evaluated by Interleukin-6 or C-Reactive Protein in Critically Ill Patients: Results From the FROG-ICU Study.
C-reactive protein
Sequential organ failure assessment
Simplified Acute Physiology Score
biomarkers
critical illness
interleukin-6
sepsis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
02
2022
accepted:
28
03
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
The prognostic impact of high concentration of interleukin-6 (IL-6) or C-reactive protein (CRP), two routinely available markers of systemic inflammation in the general population of critically ill patients, remains unclear. In a large cohort of critically ill patients including septic and non-septic patients, we assessed the relationship between baseline IL-6 or CRP and mortality, organ dysfunction, and the need for organ support. This was an ancillary analysis of the prospective French and euRopean Outcome reGistry in Intensive Care Units (FROG-ICU) study including patients with a requirement for invasive mechanical ventilation and/or vasoactive drug support for more than 24 h following intensive care unit (ICU) admission. The primary objective was to determine the association between baseline IL-6 or CRP concentration and survival until day 90. Secondary outcomes included organ dysfunction as evaluated by the Sequential Organ Failure Assessment (SOFA) score, and the need for organ support, including vasopressors/inotropes and/or renal replacement therapy (RRT). Median IL-6 and CRP concentrations ( IL-6 appears to be preferred over CRP to evaluate critically ill patients' prognoses.
Sections du résumé
Background
The prognostic impact of high concentration of interleukin-6 (IL-6) or C-reactive protein (CRP), two routinely available markers of systemic inflammation in the general population of critically ill patients, remains unclear. In a large cohort of critically ill patients including septic and non-septic patients, we assessed the relationship between baseline IL-6 or CRP and mortality, organ dysfunction, and the need for organ support.
Methods
This was an ancillary analysis of the prospective French and euRopean Outcome reGistry in Intensive Care Units (FROG-ICU) study including patients with a requirement for invasive mechanical ventilation and/or vasoactive drug support for more than 24 h following intensive care unit (ICU) admission. The primary objective was to determine the association between baseline IL-6 or CRP concentration and survival until day 90. Secondary outcomes included organ dysfunction as evaluated by the Sequential Organ Failure Assessment (SOFA) score, and the need for organ support, including vasopressors/inotropes and/or renal replacement therapy (RRT).
Results
Median IL-6 and CRP concentrations (
Conclusion
IL-6 appears to be preferred over CRP to evaluate critically ill patients' prognoses.
Identifiants
pubmed: 35634339
doi: 10.3389/fimmu.2022.868348
pmc: PMC9134087
doi:
Substances chimiques
Interleukin-6
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
868348Informations de copyright
Copyright © 2022 Picod, Morisson, de Roquetaillade, Sadoune, Mebazaa, Gayat, Davison, Cotter and Chousterman.
Déclaration de conflit d'intérêts
BC was a member of an advisory board for Roche diagnostic. BD and GC are employees of Momentum Research and who received research grants from Abbott Laboratories, Amgen, Celyad, Cirius Therapeutics, Corteria Pharmaceuticals, Roche Diagnostics, Sanofi, Sulfagenix, Windtree Therapeutics Inc., and XyloCor Therapeutics Inc. CR received a research grant from Zoll Foundation. AM received speaker’s honoraria from Abbott, Novartis, Orion, Roche, and Servier, and fees as a member of the advisory board and/or steering committee from Cardiorentis, Adrenomed, MyCartis, Neurotronik, and Sphingotec. EG received a research grant from Sphingotec, and consultancy fees from Magnisense and Roche Diagnostics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Intensive Care Med. 2006 Sep;32(9):1344-51
pubmed: 16799774
Anaesth Intensive Care. 2011 Sep;39(5):854-61
pubmed: 21970129
Crit Care. 2018 Jan 18;22(1):8
pubmed: 29347987
Int J Cardiol. 2021 Jan 1;322:191-196
pubmed: 32841617
Front Immunol. 2018 Apr 13;9:754
pubmed: 29706967
J Crit Care. 2010 Dec;25(4):657.e7-12
pubmed: 20381293
Lancet. 2004 Jan 17;363(9404):203-9
pubmed: 14738793
Immunol Today. 1994 Feb;15(2):74-80
pubmed: 7512342
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Am J Physiol Cell Physiol. 2018 May 1;314(5):C589-C602
pubmed: 29351406
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Am J Hum Genet. 2005 Jul;77(1):64-77
pubmed: 15897982
J Exp Med. 1989 Jan 1;169(1):333-8
pubmed: 2783334
J Immunol. 2013 Sep 1;191(5):2495-502
pubmed: 23894199
Immunol Invest. 2010;39(8):849-62
pubmed: 20718660
BMC Anesthesiol. 2015 Oct 12;15:143
pubmed: 26459405
Am J Hum Genet. 2008 May;82(5):1185-92
pubmed: 18439548
Am J Respir Crit Care Med. 2013 Jan 15;187(2):160-9
pubmed: 23220920
Br J Haematol. 2001 Oct;115(1):3-12
pubmed: 11722403
Crit Care Med. 2006 Aug;34(8):2035-42
pubmed: 16775569
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Arch Intern Med. 2007 Aug 13-27;167(15):1655-63
pubmed: 17698689
Crit Care Med. 2002 Sep;30(9):1987-94
pubmed: 12352031
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120